Nanoscale immunoconjugates (NICs), which deliver ICIs, covalently attached on a natural biopolymer scaffold, across the BBB using transferrin receptor (TfR)-mediated transcytosis, or via angiopep-2 (AP-2)- LDLR-related protein 1 (LRP1), were shown to outperform free ICIs in increasing TILs and improving survival in a murine glioma model (71). This evidence concerns the gene LRP1 and central nervous system cancer.